De novo biosynthesis of meroterpenoid grifolic acid in Yarrowia lipolytica

Grifolic acid, a potent bioactive meroterpenoid derived from fungi, shows great antitumor and antimicrobial properties. Nevertheless, the difficulty of large-scale chemical production and its minimal presence in natural environments hinder its path toward clinical translation. We developed a de novo grifolic acid biosynthetic route by leveraging the robust metabolic capabilities of the oleaginous yeast Yarrowia lipolytica . By improving the precursor malonyl-CoA supply through ACC1 overexpression and spatially targeting the fungal polyketide synthase ArmB to the vacuolar compartment, we enhanced orsellinic acid accumulation to 8.50 mg/L. We next leveraged AI-guided molecular docking and deep learning kinetic predictions (CataPro and UniKP) to screen candidate enzymes for coupling orsellinic acid with farnesyl pyrophosphate (FPP), identifying StbC from Stachybotrys bisbyi as the optimal prenyltransferase for coupling the polyketide with the terpenoid moieties. Integrating the heterologous module with efflux pump engineering (overexpressing native Pleiotropic Drug Resistance ABC transporters) and blocking the competing β-oxidation pathway (through HBD1 deletion) relieved intracellular toxicity and minimized carbon loss. Under optimized conditions using a two-stage glucose-growth and glycerol-supplementation fed-batch regime, the engineered strain produced grifolic acid at 30.5 mg/L in a shaker flask. This work represents the first successful de novo production of grifolic acid in Y. lipolytica , validating a holistic metabolic engineering strategy for the sustainable synthesis of complex meroterpenoids.

Authors

Institutions

Publication Details

Journal
Synthetic and Systems Biotechnology
Published
2026-11-12
DOI
https://doi.org/10.1016/j.synbio.2026.10.015
Primary Topic
Microbial Natural Products and Biosynthesis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

De novo biosynthesis of meroterpenoid grifolic acid in Yarrowia lipolytica

Pornpatsorn Lertphadungkit, Idan Cohen, Yuxiang Hong, Zizhao Wu et al.
Synthetic and Systems Biotechnology
Microbial Natural Products and Biosynthesis
article

De novo biosynthesis of meroterpenoid grifolic acid in Yarrowia lipolytica

Pornpatsorn Lertphadungkit, Idan Cohen, Yuxiang Hong, Zizhao Wu, Peng Xu, Rijin Yao, Jinpeng Wang, Bo Zhou, Gil Bar-Sela
article en

Abstract

Grifolic acid, a potent bioactive meroterpenoid derived from fungi, shows great antitumor and antimicrobial properties. Nevertheless, the difficulty of large-scale chemical production and its minimal presence in natural environments hinder its path toward clinical translation. We developed a de novo grifolic acid biosynthetic route by leveraging the robust metabolic capabilities of the oleaginous yeast Yarrowia lipolytica . By improving the precursor malonyl-CoA supply through ACC1 overexpression and spatially targeting the fungal polyketide synthase ArmB to the vacuolar compartment, we enhanced orsellinic acid accumulation to 8.50 mg/L. We next leveraged AI-guided molecular docking and deep learning kinetic predictions (CataPro and UniKP) to screen candidate enzymes for coupling orsellinic acid with farnesyl pyrophosphate (FPP), identifying StbC from Stachybotrys bisbyi as the optimal prenyltransferase for coupling the polyketide with the terpenoid moieties. Integrating the heterologous module with efflux pump engineering (overexpressing native Pleiotropic Drug Resistance ABC transporters) and blocking the competing β-oxidation pathway (through HBD1 deletion) relieved intracellular toxicity and minimized carbon loss. Under optimized conditions using a two-stage glucose-growth and glycerol-supplementation fed-batch regime, the engineered strain produced grifolic acid at 30.5 mg/L in a shaker flask. This work represents the first successful de novo production of grifolic acid in Y. lipolytica , validating a holistic metabolic engineering strategy for the sustainable synthesis of complex meroterpenoids.

Synthetic and Systems BiotechnologyVol. 20
Technion – Israel Institute of Technology (IL), Emek Medical Center (IL), Shantou University (CN), Ji Hua Laboratory (CN), Cancer Hospital of Shantou University Medical College (CN), Guangdong Technion-Israel Institute of Technology (CN)
Li Ka Shing Foundation, National Natural Science Foundation of China
Microbial Natural Products and Biosynthesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon